rs290475 — TCF7L2 TCF7L2 Beta Cell Function Depth Variant

Intronic TCF7L2 variant tagging a distinct haplotype with emerging evidence for effects on beta cell transcriptional regulation through the Wnt/beta-catenin axis

See your personal result for TCF7L2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

A Third Window Into TCF7L2 — the Wnt Gateway for Blood Sugar

The TCF7L2 gene holds a unique distinction in human genetics: it is the single strongest common genetic predictor of type 2 diabetes, with effects replicated across every major ethnic population studied. Two variants — rs7903146 and rs12255372 — are already well-characterized in this encyclopedia. rs290475 sits ~26,000 base pairs upstream of their coding region in intron 4, potentially tagging a distinct functional haplotype within the same gene-regulatory landscape.

The Mechanism

TCF7L2 encodes a [transcription factor | a protein that controls which genes are switched on or off by binding to specific DNA sequences] in the canonical Wnt/beta-catenin signaling pathway11 Wnt/beta-catenin signaling pathway
a fundamental cell-communication cascade governing development, stem cell maintenance, and metabolic homeostasis. In the pancreatic beta cell, TCF7L2 does two critical jobs: it drives expression of the GLP-1 receptor22 GLP-1 receptor
the receptor for GLP-1, a gut hormone that potently stimulates insulin secretion after meals and regulates the beta-cell's survival via the p53 pathway. Beta cell-specific TCF7L2 knockout in mice33 Beta cell-specific TCF7L2 knockout in mice
Mitchell et al. Selective disruption of Tcf7l2 in the pancreatic β cell impairs secretory function and lowers β cell mass. Hum Mol Genet, 2015 reduces GLP-1 receptor expression by ~40% and impairs both glucose-stimulated and GLP-1-stimulated insulin secretion.

In the liver, TCF7L2 plays an opposing but complementary role. Insulin normally upregulates hepatic TCF7L2 expression, which then acts as a brake on gluconeogenesis44 gluconeogenesis
the liver's ability to manufacture new glucose from non-sugar precursors such as amino acids and glycerol. Knocking out hepatic TCF7L255 Knocking out hepatic TCF7L2
Ip et al. AJP Endocrinol Metab, 2012 increases glucose output, while overexpression dampens it — evidence that TCF7L2 is a direct molecular link between the Wnt pathway and fasting blood sugar.

The deep intronic position of rs290475 (c.484-26924 in the major transcript) suggests it acts as a regulatory tag — influencing nearby transcription factor binding sites, chromatin accessibility, or splice-site efficiency rather than altering the protein sequence. Intronic variants in this region of TCF7L2 have been shown to alter islet-specific enhancer activity, and rs290475 may mark a distinct regulatory element not captured by rs7903146.

The Evidence

rs290475 has no direct type 2 diabetes GWAS entry in the GWAS Catalog as of 2026. Its most prominent documented associations — identified via proxy analysis — are with bipolar disorder in the context of elevated BMI66 bipolar disorder in the context of elevated BMI
Winham et al. Genome-wide association study of bipolar disorder accounting for effect of body mass index identifies a new risk allele in TCF7L2. Mol Psychiatry, 2014 and with neuroticism conditioned on educational/cognitive phenotypes. This is a hallmark of pleiotropic TCF7L2 variants — the Wnt pathway governs both metabolic and neurodevelopmental programs, and intronic regulatory variants can produce tissue-specific expression effects that manifest differently in brain versus pancreas versus liver.

The broader TCF7L2 locus literature documents the mechanism clearly: risk allele carriers show impaired incretin-mediated insulin secretion77 risk allele carriers show impaired incretin-mediated insulin secretion
Florez et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. NEJM, 2006, reduced beta cell mass, and increased hepatic glucose output. A global meta-analysis of 17,000+ T2D cases88 global meta-analysis of 17,000+ T2D cases
Cauchi et al. J Mol Med, 2007 established the TCF7L2 locus OR of 1.46 — the largest effect size for any common T2D variant. Because rs290475 tags this same regulatory region, its C-allele carriers may share a portion of that risk through a haplotype distinct from the primary rs7903146 signal, but direct confirmation awaits fine-mapping studies with phenotyped T2D cohorts.

Practical Actions

The evidence for rs290475-specific dietary guidance is indirect, extrapolated from the broader TCF7L2 locus and GLP-1/hepatic mechanism. If you carry the C allele, the most relevant actions target:

  1. Incretin optimization — meals and foods that stimulate GLP-1 secretion most effectively (high-fiber, low-glycemic-index foods; legumes; fermented dairy) support the impaired GLP-1 signaling pathway.
  2. Hepatic glucose management — spreading carbohydrate intake across multiple smaller meals reduces peak gluconeogenic stimulus and leverages the meal-responsive TCF7L2/Wnt axis in the liver.
  3. Metabolic monitoring — given the locus-level evidence for T2D risk, periodic fasting glucose and HbA1c checks are prudent, especially as a complement to rs7903146 and rs12255372 results.

Interactions

This variant co-localizes with rs7903146 and rs12255372 in the TCF7L2 regulatory haplotype block. Carriers of C at rs290475 who also carry T at rs7903146 represent a subset with potential additive or independent effects on TCF7L2 expression levels in pancreatic islets and liver. Future fine-mapping studies at this locus may resolve whether rs290475 tags an independent causal variant or is in partial LD with the primary signal.

Nutrient Interactions

dietary fat altered_metabolism
carbohydrate altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

TT Common Haplotype Normal

Common TCF7L2 haplotype at this depth variant

You carry the most common genotype at this position in TCF7L2. About 64% of people of European descent share this genotype. The T allele is the population-major allele globally and is not associated with elevated T2D risk at this specific locus. Your TCF7L2 beta cell and hepatic glucose regulation programs are not affected by this depth variant.

CT One C Allele Intermediate

One copy of the rare TCF7L2 haplotype marker

TCF7L2's pleiotropic role in the Wnt pathway means that intronic regulatory variants here can influence tissue-specific gene expression patterns. In heterozygotes, one normal T-allele regulatory sequence and one C-allele sequence are present — the net expression effect is likely intermediate relative to TT and CC. The GWAS associations at this locus position (bipolar disorder with BMI interaction; neuroticism) reflect TCF7L2's dual role in metabolic and neural Wnt signaling. Given the locus-level T2D evidence and the emerging depth-variant hypothesis, periodic metabolic monitoring is a reasonable precaution.

CC Homozygous C Allele High Risk

Two copies of the rare TCF7L2 haplotype marker

The CC genotype places you in a rare minority at this locus. The C allele is enriched in South Asian populations (31% allele frequency) relative to European (20%) or African (6%), mirroring the elevated T2D prevalence in South Asian populations that is only partially explained by the well-studied rs7903146 variant. This pattern raises the hypothesis that rs290475-C (or a variant in LD with it) contributes to T2D risk in populations where the primary rs7903146-T risk allele is rare — though this remains an active research question.

TCF7L2 biology at the cellular level provides the mechanism: impaired TCF7L2 expression in pancreatic islets reduces GLP-1 receptor transcription by ~40%, blunts glucose-stimulated insulin secretion, and accelerates beta-cell apoptosis. In liver, reduced TCF7L2 activity lifts the brake on gluconeogenesis, increasing fasting glucose. Both effects converge on the classic T2D phenotype of relative insulin deficiency combined with elevated hepatic glucose output.